Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of “Moderate Buy” by Analysts

Vir Biotechnology, Inc. (NASDAQ:VIR) has received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $34.83.

Several equities research analysts have issued reports on VIR shares. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. JPMorgan Chase & Co. upped their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a report on Friday, January 31st. Finally, Barclays decreased their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th.

Insiders Place Their Bets

In other news, Director Vicki L. Sato sold 10,960 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 15.60% of the company’s stock.

Institutional Trading of Vir Biotechnology

Several hedge funds have recently added to or reduced their stakes in VIR. Rhumbline Advisers lifted its holdings in shares of Vir Biotechnology by 0.5% in the 4th quarter. Rhumbline Advisers now owns 236,681 shares of the company’s stock worth $1,737,000 after acquiring an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,999 shares during the last quarter. Blue Trust Inc. lifted its position in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in Vir Biotechnology by 10.7% during the 4th quarter. Teacher Retirement System of Texas now owns 26,440 shares of the company’s stock valued at $194,000 after buying an additional 2,556 shares during the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in Vir Biotechnology by 1.4% during the 3rd quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock valued at $1,455,000 after buying an additional 2,600 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Stock Down 3.3 %

NASDAQ:VIR opened at $9.07 on Friday. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -2.31 and a beta of 0.64. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The company’s 50 day moving average is $9.05 and its 200-day moving average is $8.47.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).